N eurofibromatosis type 2 (NF2) is a genetic condition typified by bilateral vestibular schwannomas, but also causing a range of other tumors both in the central and peripheral nervous system. These tumors include other cranial, spinal, peripheral nerve and intradermal schwannomas, cranial and spinal meningiomas, and intrinsic tumors, which are predominantly spinal ependymomas. These are summarized by the Manchester criteria. 1 In the original criteria developed from National Institutes of Health (NIH) consensus from 1987, the intrinsic tumors were described generically as gliomas rather than as ependymomas specifically. This reflected a radiological opinion on tumors from the 1980s rather than from histological diagnosis. We have been concerned that this imprecise nomenclature has subsequently resulted in extrapolation of the glioma criterion to include malignant glioma, 2 a presumption ABBREVIATIONS: GBM, glioblastoma multiforme; NF1, neurofibromatosis type 1; NF2, neurofibromatosis type 2, NIH, National Institutes of Health; WHO, World Health Organization that does not marry with our own clinical impression. Rather, it was our impression, both from our own NF2 cohort and our review of the literature that malignant glioma only appears in the context of NF2 after either radiotherapy, including stereotactic radiosurgery of vestibular schwannomas. The confusion in the literature over whether high-grade gliomas are a feature of NF2 and as to whether they should be part of NF2 diagnostic criteria, or, alternatively, recognized as a potential risk of irradiation, has lead us to re-examine this issue. We have interrogated the Manchester NF2 database of 1253 NF2 patients for the presence of histologically proven high-grade gliomas and reviewed the literature.
METHODS
A review was undertaken of the NF2 database available to the senior author (DGE), which has ethical approval from the Central Manchester Ethics Committee. Patient consent was not necessary because there is no patient identifiable information. The purpose was to describe the nature of the intracranial intra-axial tumors. The NF2 database consists of 1253 patients. This consists of families who fulfill at least 
RESULTS
Five hundred ninety patients were male and 663 female. Of the 1253 NF2 patients in the database, the mean age at diagnosis was 32.46 yr (range 0.2-82). Two hundred forty-four patients had died, with a median age of 39 yr (range 14.4-84.9 yr). There were 1009 patients known to be alive at last follow-up. The median age of this group was 41.3 yr (range 1.0-90.5 yr). Eight hundred twelve of 1168 (69.5%) had known mutations. Six hundred fortysix were germline (constitutional) mutations with 176 mosaics whilst 346 had no identified mutation from blood DNA. Eightyfive patients had not undergone mutation testing.
There were 11 123.1 yr of follow-up from diagnosis in 1148 patients with information on date of diagnosis giving a mean follow-up of 8.92 yr per patient. Follow-up from birth to last follow-up was 51 525.2 yr.
In the whole group, there was 1 case of malignant grade IV glioma (glioblastoma multiforme [GBM]) reported. This single case occurred after stereotactic radiosurgery for a vestibular schwannoma.
There were 3 pathologically proven low-grade intracranial intrinsic tumors, 2 optic nerve pilocytic astrocytomas and a gliofibroma. Recognizing that pilocytic astrocytomas are a defining feature of neurofibromatosis type 1 (NF1), the 2 patients with pilocytic astrocytomas had no features of NF1 and met all the inclusion criteria for NF2. There was 1 spinal pilocytic astrocytoma that was removed in childhood. There were no cases of malignant gliomas. One hundred forty-eight of 889 (16.6%) with data on spinal imaging had radiological evidence of a uni-or multifocal intrinsic spinal cord or, much less frequently, lower brainstem lesion consistent with an ependymoma. No patient had an isolated intrinsic lesion of the brain stem alone. Six of the spinal tumors have been confirmed as grade 1 ependymoma at surgery.
Of the 10 cases of glioma published by the senior author in 1992 1 none were histologically confirmed as high-grade glioma and none of these patients subsequently died of their intrinsic brain/spinal cord tumor, effectively ruling out a high-grade glioma (4 are still living), although none had undergone a surgical excision or biopsy.
DISCUSSION
In the 1253 total cases in the database, there was only 1 case of malignant glioma. This occurred 3 yr after stereotactic radiosurgery, as reported in the Sheffield series. 2 Outside of this single case, the striking feature of this large series is both the rarity of intracranial intra-axial lesions and the total absence of malignant glioma in the nonirradiated brain or spine. Only 2 such intraaxial brain tumors were found, both were benign. By comparison, intra-axial spinal cord tumors are relatively common, occurring in up to 31% of NF2 series 3 (16.6% this series). It is now well recognized that these spinal cord tumors are ependymomas. 4 They are, therefore, within the World Health Organization classification of gliomas, 5 and therefore the original NIH criteria and the subsequent Manchester modification were accurate, if somewhat imprecise and nonspecific. It would appear that subsequently it has been assumed that NF2 can be associated with any glial tumor and therefore potentially a malignant glioma.
The case in our series is described by Rowe et al 2 in their series of outcomes from radiosurgery and is of a woman treated for a 1.8 cm 3 vestibular schwannoma in 2000 with a marginal dose of 14 Gy. She developed a malignant glioma within 3 yr of treatment and died within 6 mo of diagnosis. Details of where the lesion arose in relation to the treated schwannoma are not published, to our knowledge. It was estimated from the treatment plan that 24 cm 3 of the brain received more than 2 Gy and 54 cm 3 of the brain received 1 to 2 Gy. In the absence of details as to the relationship between the laterality of the treated schwannoma and the site of the malignant glioma, it is not possible to say with any confidence whether this lesion meets the Cahan criteria 6 for radiation-induced neoplasia. With regard to these criteria, it is clearly histologically distinct from the original vestibular schwannoma, and we believe we have shown in this paper that NF2 does not predispose to malignancy. The latency is no more than 3 yr, relatively brief by Cahan criteria. 6 It is also the case that glioblastoma has been reported after stereotactic radiosurgery to a vestibular schwannoma in 2 cases, neither of them NF2. 7, 8 In the non-NF2 situation, where the numbers of irradiated vestibular schwannomas throughout the world is much higher, the possibility of coincidental development of a GBM is plausible, but the presence of 1 case of GBM in NF2 only after radiotherapy and none in unirradiated cases still requires explanation. Rowe et al 2 argue that given that 4% of NF2 patients develop gliomas, it is not clear that there is an increased risk in their material. This figure of 4% relates to the paper of 1992, 1,2 subsequently known as defining the "Manchester criteria" for NF2 and widely accepted since (Table 1) . This paper describes astrocytomas in 4.1% of cases and ependymomas in 2.5% of cases. It specifically states that "astrocytomas and ependymomas were low grade and affected the lower brain stem and upper cervical cord, although one astrocytoma had spread to involve the entire medulla of the spine." We now know too that these lesions are almost exclusively ependymomas 4,9 not astrocytomas and can occur throughout the spinal cord from the medulla of the brain stem to the conus of the spinal cord. We have shown from the data we present here that malignant glioma is, with the exception of the case described by Rowe et al, 2 not a feature of NF2. Therefore, more than 20 yr after the description of the criteria for NF2, there is a need to clarify that the term "glioma" in the Manchester criteria does not refer to malignant glioma. The annual incidence rate for astrocytic tumors in the UK is 5 per 100 000 annually, with 63% being high grade. 10 As such, in 11 000 yr of follow-up, one might have seen 1 high-grade glioma in our NF2 series by chance (expected 0.35), yet none occurred in nonirradiated patients. From birth, one might have expected 1.62 high-grade gliomas in 51 512 yr of follow-up, yet the only one to occur was postirradiation. The 4 low-grade (nonependymoma) gliomas would be in excess of the 24% of 5/100 000 rate with an expected incidence of 0.13 indicating a relative risk of 23 fold.
The fact that we have failed to find a single case of malignant glioma outside of an irradiated case, as well as the acceptance that the spinal cord lesions are ependymomas, would be in keeping with genetic studies of sporadic gliomas and ependymomas in the literature (Table 2) . Although we did not have information on spinal imaging in 364/1253 (29%) of cases, all had undergone cranial magnetic resonance imaging.
Rubio et al 11 screened 8 ependymomas and 30 fibrillary astrocytomas from non-NF2 cases for the NF2 gene. They found no mutation in astrocytomas but did find a mutation in spinal ependymoma. They concluded that NF2 gene mutations are not important for astrocytoma and oligodendroglioma tumorigenesis. The absence of NF2 mutations in glioma is confirmed by other studies. 12, 13, 14 In total, these 4 papers studied 177 gliomas and failed to find a single NF2 mutation. The same absence of an NF2 mutation was found in a study of another intrinsic tumor not found in NF2 (oligodendroglioma). 15 In contrast, NF2 mutations are found in some, but by no means all, sporadic spinal ependymomas 12,15-17 -18 out 58 (31%) spinal ependymomas.
CONCLUSION
In this large series of patients with NF2, we found no evidence that malignant glioma is a feature of NF2. The description in the literature of gliomas being present in NF2 relates to lowgrade spinal cord and brain stem lesions rather than supratentorial tumors such as malignant glioma. The NF2 criteria should now be clarified to reflect the lack of high-grade glioma link.
